{"id":18502,"date":"2024-05-07T08:41:41","date_gmt":"2024-05-07T08:41:41","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/atopia-therapeutics-formerly-hpvac-announces-appointment-of-dr-gregoire-chevalier-as-ceo-and-business-update\/"},"modified":"2024-05-07T08:41:41","modified_gmt":"2024-05-07T08:41:41","slug":"atopia-therapeutics-formerly-hpvac-announces-appointment-of-dr-gregoire-chevalier-as-ceo-and-business-update","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/atopia-therapeutics-formerly-hpvac-announces-appointment-of-dr-gregoire-chevalier-as-ceo-and-business-update\/","title":{"rendered":"Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update"},"content":{"rendered":"
\n

Geneva (Switzerland), May 7, 2024 \u2013\u00a0Atopia Therapeutics,<\/a> a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Gr\u00e9goire Chevalier as Chief Executive Officer (CEO). Formerly known as HpVac, the Company has repositioned itself under the new name Atopia Therapeutics to better reflect its commitment to addressing the growing global burden of atopic diseases. <\/p>\n

Gr\u00e9goire Chevalier brings over 10 years of research and drug development experience to Atopia Therapeutics. He joins the Company from Enterome, a leading French biotechnology company focused on innovative immunotherapy for cancer, where he spent the last 5 years directing several R&D programs. Throughout his career, he has demonstrated a strong ability to drive strategic initiatives and foster a culture of innovation and excellence. Gr\u00e9goire will now lead Atopia\u2019s strategy and development and strengthen the overall organization. <\/p>\n

Under Gr\u00e9goire Chevalier\u2019s leadership, Atopia Therapeutics will continue the development of novel treatments that address the underlying mechanisms of atopic diseases. Its lead compound ATP-R13 (formerly: HpVac-R13) is designed as a first-line preventive and therapeutic treatment for a number of type-2 atopic diseases, including asthma, allergic rhinitis, food allergies and atopic dermatitis. The compound has already generated promising data in preclinical studies, including beneficial effects on airway hyperresponsiveness, airway remodeling, and inflammation in mouse models of allergic asthma. <\/p>\n

\u201cAs we embark on our next phase of growth and expansion, we are thrilled to welcome Gr\u00e9goire Chevalier as the new CEO of Atopia Therapeutics,\u201d said Board Member Jacques Billy, CFO of Atopia Therapeutics. \u201cGr\u00e9goire\u2019s deep industry expertise, coupled with his passion for scientific innovation and patient-centric approach, make him the ideal leader to steer our company towards continued success.\u201d<\/p>\n

\u201cI am delighted and grateful to have the opportunity to lead Atopia Therapeutics during this exciting period of growth and transformation,\u201d said Gr\u00e9goire Chevalier, CEO of Atopia Therapeutics. \u201cI am inspired by the Company\u2019s commitment to advancing cutting-edge therapies for allergic diseases, and I look forward to working with the talented team to deliver impactful solutions for patients in need.\u201d<\/p>\n

As part of the rebranding initiative, Atopia Therapeutics has unveiled a refreshed corporate identity, including a new logo and website (www.atopiatx.com<\/u><\/a>), designed to reflect the Company\u2019s innovative spirit and forward-thinking approach.<\/p>\n

###<\/p>\n

About Atopia Therapeutics:<\/b>
Atopia Therapeutics is a leading biotech company dedicated to revolutionizing the treatment of allergic diseases via novel microbiome-based therapeutics. Formerly known as HpVac, Atopia Therapeutics is committed to developing innovative therapies that target the underlying causes of allergies, offering hope and relief to patients worldwide.
Its lead compound ATP-R13 (formerly: HpVac-R13) is designed as an oral first-line preventive and therapeutic treatment against asthma, eczema, food allergies, and related type-2 atopic diseases. ATP-R13 remains in the stomach, interacts with dendritic cells and macrophages in the host\u2019s lamina propria<\/i>, and induces the production of tolerizing dendritic cells and regulatory T cells (Tregs), which then migrate to draining lymph nodes, before dispersing to other target organs (lungs, skin, etc.). ATP-R13 has been shown to induce a state of tolerance and reduce inflammation in preclinical studies.
Atopia Therapeutics is based in Geneva, Switzerland. For more information, please visit www.atopiatx.com<\/u><\/a>.<\/p>\n

For media inquiries or further information, please contact:<\/p>\n

Atopia Therapeutics, SA<\/b>
Dr. Jeffrey Shaw, COO
Campus Biotech \u2013 Innovation Center
15, Avenue de S\u00e9cheron
CH-1202 Geneva, Switzerland
info@atopiatx.com<\/u><\/a>
Tel. +41 22 794 40 20
Tel. +41 78 664 55 83<\/p>\n

Media Inquiries<\/b>
akampion
Dr. Ludger Wess \/ Ines-Regina Buth
Managing Partners\u00a0
info@akampion.com<\/u><\/a>
Tel. +49 40 88 16 59 64 \/
Tel. +49 30 23 63 27 68<\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

Geneva (Switzerland), May 7, 2024 \u2013\u00a0Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Gr\u00e9goire Chevalier as Chief Executive Officer (CEO). Formerly known as HpVac, the Company has repositioned itself under the new name Atopia Therapeutics to better reflect its commitment to addressing the growing […]<\/p>\n","protected":false},"author":2,"featured_media":18503,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/media\/YzUxNWNjMjctYjhkNC00ZDlmLWJjMTYtZDZmMDFlY2NmYjZhLTEwMzc0NTQ=\/tiny\/AKAMPION.png","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-18502","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/18502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/comments?post=18502"}],"version-history":[{"count":0,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/18502\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media\/18503"}],"wp:attachment":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media?parent=18502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/categories?post=18502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/tags?post=18502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}